• 7028 malaria professionals are enjoying the free benefits of MalariaWorld today

Artesunate-Mefloquine

Polymorphisms of Molecular Markers of Antimalarial Drug Resistance and Relationship with Artesunate-Mefloquine Combination Therapy in Patients with Uncomplicated Plasmodium falciparum Malaria in Thailand

Author(s): 
Poonuch Muhamad, Papichaya Phompradit, Wannapa Sornjai, Thunyaluk Maensathian, Wanna Chaijaroenkul, Ronnatrai Rueangweerayut and Kesara Na-Bangchang
Reference: 
Am J Trop Med Hyg 2011 vol. 85 no. 3 568-572
Contact email: 
kesaratmu@yahoo.com

Analysis of gene mutation and amplification were performed by nested real-time polymerase chain reaction and SYBR Green I real-time polymerase chain reaction, respectively.

Open Access | Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience

Author(s): 
Bompart F, Kiechel J, Sebbag R, Pecoul B
Reference: 
Malaria Journal 2011, 10:143 (23 May 2011)

The speed at which ASAQ Winthrop was adopted in the field shows that this drug fits the needs of patients and health authorities.

Open Access | An Open-Label, Randomised Study of Dihydroartemisinin-Piperaquine Versus Artesunate-Mefloquine for Falciparum Malaria in Asia

Author(s): 
Neena Valecha, Aung Pyae Phyo, Sasithon Pukittayakamee, et al
Reference: 
PLoS ONE 5(7): e11880
Contact email: 
neenavalecha@gmail.com

DHA/PQP was a highly efficacious drug for P. falciparum malaria in areas where multidrug parasites are prevalent. The DHA/PQP combination can play an important role in the first-line treatment of uncomplicated falciparum malaria.

Efficacy and safety of a new pediatric artesunate-mefloquine drug formulation for the treatment of uncomplicated falciparum malaria in Gabon

Author(s): 
MK Bouyou-Akotet, M Ramharter, EB Ngoungou, MM Mamfoumbi, MP Mihindou, MA Missinou, F Kurth, S Bélard, ST Agnandji, S Issifou, JL Heidecker, S Trapp, PG Kremsner, M Kombila
Reference: 
Wiener Klinische Wochenschrift, Volume 122, Numbers 5-6 / March, 2010 Pages 173-178
Contact email: 
valentine_favry@yahoo.fr

Pediatric drug formulations of artemisinin combination therapies are urgently needed for improving the treatment of children suffering from uncomplicated malaria. The aim of this clinical trial was to evaluate the efficacy, safety and tolerability of a novel pediatric fixed-dose granule formulation of artesunate-mefloquine and a new co-blister tablet formulation.

Open Access | Compliance with a three-day course of artesunate-mefloquine combination and baseline anti-malarial treatment in an area of Thailand with highly multidrug resistant falciparum malaria

Author(s): 
Kanungnit Congpuong, Pongwit Bualombai, Vick Banmairuroi, Kesara Na-Bangchang
Reference: 
Malaria Journal 2010, 9:43 (4 February 2010)
Contact email: 
kesaratmu@yahoo.com

The authors discuss the compliance associated with a three-day AS-MQ regimen following a recent change in the treatment guidelines for uncomplicated falciparum malaria in Thailand. The patient data are supported by whole blood/plasma drug levels. In malaria treatment compliance remains a major factor determining effectiveness.

Therapeutic Efficacy and Effects of Artesunate-Mefloquine and Mefloquine Alone on Malaria-Associated Anemia in Children with Uncomplicated Plasmodium falciparum Malaria in Southwest Nigeria

Author(s): 
Akintunde Sowunmi, Grace O. Gbotosho, Christian Happi, Titilope Okuboyejo, Onikepe Folarin, Sulayman Balogun, AND Obaro Michael
Reference: 
Am J Trop Med Hyg 2009;81 979-986
Contact email: 
akinsowunmi@hotmail.com

Both regimens were well tolerated. AMQ clears parasitemia and reduces gametocyte carriage more rapidly and causes lesser fall in hematocrit than MQ, but both regimens are effective treatment of uncomplicated P. falciparum malaria in Nigerian children.

Syndicate content